Skip to main content
. Author manuscript; available in PMC: 2022 Apr 8.
Published in final edited form as: Bioorg Med Chem. 2021 May 30;43:116242. doi: 10.1016/j.bmc.2021.116242

Figure 5.

Figure 5.

Co-adjuvanticity of potent analogs with MPLA. Left: mice (n=5 per group) were immunized on day 0 and day 21 with antigen (OVA, 20 μg/mice), MPLA (10 ng/mice) and compound 1, 12d, 18q or 54h (50 nmol/mice). The immunized mice were bled on day 28 and OVA-specific IgG titers were measured using ELISA. Left: Box and whisker plot showing statistically significant enhancement of antibody titers for compounds 18q and 54h when co-adjuvanted with MPLA compared to MPLA alone. **p<0.05 compared to MPLA group using Bartlett’s one-way ANOVA followed by Dunnett’s post hoc testing. Right: Pearson two-tailed correlation ((P<0.0007, R2 = 0.9986) of mean (positive standard deviation) of OVA-specific IgG titers and EC50 values obtained for NF-κB SEAP assay in THP-1 cells with LPS.